Revance Therapeutics Inc.

(RVNC) Trade

By |

Profile

Revance Therapeutics Inc is a clinical-stage biotechnology company. It is focused on the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company's proprietary peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. The Company is pursuing clinical development for RT002 injectable in a broad spectrum of aesthetic and therapeutic indications. It holds rights for all indications of RT002 injectable and RT001 topical, and the pharmaceutical uses of its proprietary peptide technology.

Contact Information

Website: www.revance.com
Email: contacts@revance.com
Main Phone: +1 510 742-3400
Address: 7555 Gateway Boulevard
State: CA
City / Town: Newark
Country: USA
Postal Code: 94560

Issuer Information

Exchange: NSD
CEO: L. Daniel Browne
Employees: 170
NAICS: Pharmaceutical Preparation Manufacturing(325412)


Gathering Data... Please wait

Profile

Revance Therapeutics Inc is a clinical-stage biotechnology company. It is focused on the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company's proprietary peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. The Company is pursuing clinical development for RT002 injectable in a broad spectrum of aesthetic and therapeutic indications. It holds rights for all indications of RT002 injectable and RT001 topical, and the pharmaceutical uses of its proprietary peptide technology.

Contact Information

Website: www.revance.com
Email: contacts@revance.com
Main Phone: +1 510 742-3400
Address: 7555 Gateway Boulevard
State: CA
City / Town: Newark
Country: USA
Postal Code: 94560

Issuer Information

Exchange: NSD
CEO: L. Daniel Browne
Employees: 170
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 11.89 $ 0.23 (1.97%)
Last Price 11.89 Change $ 0.23 Change % 1.97 Tick N/A
Bid 11.01 Bid Size 100.00 Ask 14.97 Ask Size 200.00
Open 11.61 High 11.92 Low 11.33 Prev Close 11.66
Last Trade Volume 370,185 52 Wk Hi 32.45 52 Wk Low 10.51
Market Cap 523.2 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 44,006,580.00 EPS (TTM) -3.82 PE Ratio N/A Exchange NSD
  Last 3 Mo Last 12 Mo
Number of Insider Trades 23 57
Number of Buys 16 34
Number of Sells 7 23
Net Activity 66359 165621
Last 10 Buys Shares
Philip J. Vickers 1,000
Philip J. Vickers 1,000
Mark J. Foley 1,000
Mark J. Foley 1,000
Lauren P. Silvernail 1,000
Lauren P. Silvernail 1,000
L. Daniel Browne 1,000
Last 10 Sell Shares
Lauren P. Silvernail 1,000
Lauren P. Silvernail 1,000
Phyllis I. Gardner 1,000
L. Daniel Browne 1,000
L. Daniel Browne 1,000
Lauren P. Silvernail 1,000
Lauren P. Silvernail 1,000
L. Daniel Browne 1,000
Lauren P. Silvernail 1,000
L. Daniel Browne 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 58 58 58 58
Low Target Price Estimate 34 34 34 34
Mean Target Price Estimate 47.38 47.38 47.38 47.38
Standard Deviation 7.76 7.76 7.76 7.76
Date of Most Recent Estimate 05/22/18 05/22/18 05/22/18 05/22/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 7 7 7 7
Moderate Buy 1 1 1 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.33 1.33 1.33 1.25